POLE2
ENSG00000100479
Target class
Unclassified protein
Chromosome
14
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Other names
- DPE2
- Target name
- POLE2
- Gene name
- DNA polymerase epsilon 2, accessory subunit
- Gene symbol
- POLE2
- Protein name
- DNA polymerase epsilon subunit 2 (DNA polymerase II subunit 2) (DNA polymerase epsilon subunit B)
- Gene biotype
- Protein coding
- Gene family
- DNA polymerases
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 28
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 13.31
- Tissue specificity (Gini)
- 0.488
- Tissue specificity (tau)
- 0.897
- KEGG gene identifiers
- hsa:5427
- Protein interaction confidence
- 0.874853
- Protein interaction partners
- 75
- R-HSA-110314
- R-HSA-5651801
- R-HSA-5656169
- R-HSA-5685942
- R-HSA-5696397
- R-HSA-5696400
- R-HSA-6782135
- R-HSA-6782210
- R-HSA-68952
- R-HSA-68962
- End position
- 49688422
- Start position
- 49643555
- Chromosome
- 14
- Strand
- Reverse
- Nucleus.
- Nuclear bodies
- Nucleoplasm
- Vesicles
- Tissue specificity (tau)
- 0.896971
- Expression inequality (Gini)
- 0.48822
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 13.31
- Cells - Cultured fibroblasts
- 5.29
- Testis
- 4.61
- Esophagus - Mucosa
- 4.14
- Cervix - Ectocervix
- 3.16
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes13.31
- Cells - Cultured fibroblasts5.29
- Testis4.61
- Esophagus - Mucosa4.14
- Cervix - Ectocervix3.16
- Vagina3.12
- Cervix - Endocervix3.01
- Small Intestine - Terminal Ileum2.42
- Uterus2.27
- Skin - Sun Exposed (Lower leg)2.19
- Ovary2.18
- Skin - Not Sun Exposed (Suprapubic)2.11
- Spleen2.04
- Colon - Transverse1.88
- Breast - Mammary Tissue1.83
- Fallopian Tube1.74
- Prostate1.71
- Nerve - Tibial1.69
- Adipose - Subcutaneous1.56
- Lung1.54
- Bladder1.52
- Thyroid1.46
- Minor Salivary Gland1.22
- Stomach1.2
- Artery - Coronary1.15
And 29 more, listed on the interactive page.
- GO:0006260
- GO:0006261
- GO:0006281
- GO:0005654
- GO:0008622
- GO:0016604
- GO:0003887
- GO:0005515
Related records
Trials (4,736)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Drugs (7)
- Aspacytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Clofarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Cytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Fludarabine phosphate DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine hydrochloride DNA polymerase (alpha/delta/epsilon) inhibitor
- Troxacitabine DNA polymerase (alpha/delta/epsilon) inhibitor